¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"high signal intensity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • radiant intensity
    ¹æ¿­°­µµ, ¹æ»ç°­µµ
  • analog signal
    ¾Æ³¯·Î±×½ÅÈ£
  • electric signal
    Àü±â½ÅÈ£
  • flow signal
    È帧½ÅÈ£, À¯µ¿½ÅÈ£
  • low signal
    ¾àÇѽÅÈ£, Àú½ÅÈ£
  • MR signal
    ÀÚ±â°ø¸í½ÅÈ£
  • off-resonance signal
    ÀÌÅ»°ø¸í½ÅÈ£
  • signal
    ½ÅÈ£
  • signal alteration
    ½ÅÈ£º¯°æ
  • signal amplitude
    ½ÅÈ£ÁøÆø
  • signal anxiety
    ½ÅÈ£ºÒ¾È
  • signal averaging
    ½ÅÈ£Æò±Õ
  • signal homogeneity
    ½ÅÈ£±ÕÁú¼º
  • signal loss
    ½ÅÈ£¼Ò½Ç
  • signal oversampling
    ½ÅÈ£°ú´ÙÃßÃâ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • signal transduction
    ½ÅÈ£Àü´Þ
  • signal void
    ¹«½ÅÈ£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • maximum intensity projection
    ÃÖ´ë°­µµÅõ»ç
  • analog signal
    ¾Æ³¯·Î±×½ÅÈ£
  • signal alteration
    ½ÅÈ£º¯°æ
  • signal amplitude
    ½ÅÈ£ÁøÆø
  • signal anxiety
    ½ÅÈ£ºÒ¾È
  • signal averaging
    ½ÅÈ£Æò±Õ
  • quadrature signal detection
    ±¸Àû½ÅȣŽÁö
  • electric signal
    Àü±â½ÅÈ£
  • signal effect
    ½Åȣȿ°ú
  • flow signal
    È帧½ÅÈ£, À¯µ¿½ÅÈ£
  • signal homogeneity
    ½ÅÈ£±ÕÀϼº
  • low signal
    Àú½ÅÈ£, ³·Àº½ÅÈ£
  • signal loss
    ½ÅÈ£¼Ò½Ç
  • MR signal
    ÀÚ±â°ø¸í½ÅÈ£
  • off-resonance signal
    ÀÌÅ»°ø¸í½ÅÈ£
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intensity difference thresheld
    °­µµÆÇº°(Ë­Óø÷÷ܬ)
  • intensity duration curve
    °­µµ±â°£°î¼±
  • intensity factor
    °­µµÀÎÀÚ
  • intensity level
    °­µµ¼öÁØ(Ë­öôâ©ñÞ).
  • intensity modulated radiation therapy
    °­µµº¯Á¶ ¹æ»ç¼±Ä¡·á
  • intensity of radiation
    ¹æ»ç¼±°­µµ
  • intensity of spectral lines
    ½ºÆåÆ®·³¼±ÀÇ °­µµ.
  • intensity of turbulence
    ¿Í·ùÀÇ °­µµ.
  • intensity variable
    °­µµº¯¼ö.
  • radiant intensity
    ¹æ»ç°­µµ(Û¯ÞÒË­öô).
  • HDL (High-density lipoproteins)
    °í¹ÐµµÁö´Ü¹éÁú(ÍÔÚËÓøò·Ó±ÛÜòõ)
  • High energy phosphate
    °í¿¡³ÊÁöÀλê
  • High-density lipoprotein = HDL
    °í¹ÐµµÁö´Ü¹éÁú(ÍÔÚËÓøò·Ó±ÛÜòõ)
  • High-molecular-weight kininogen
    °íºÐÀÚ·®Å°´Ï³ëÁø
  • High-threshold cells
    °í¿ªÄ¡¼¼Æ÷(ÍÔ ö·á¬øà)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intensity modulated radiation therapy
    °­µµº¯Á¶ ¹æ»ç¼±Ä¡·á
  • intensity of radiation
    ¹æ»ç¼±°­µµ
  • intensity of spectral lines
    ½ºÆåÆ®·³¼±ÀÇ °­µµ.
  • intensity of turbulence
    ¿Í·ùÀÇ °­µµ.
  • intensity variable
    °­µµº¯¼ö.
  • isosignal intensity
    µî½ÅÈ£ °­µµ
  • low intensity void in proton flow
    ¾ç¼ºÀÚ È帧ÀÇ Àú°­µµ ¼Ò½Ç
  • lower intensity
    Àú°­µµ
  • luminous intensity
    ±¤µµ(˴̬).
  • magnetic field intensity
    ÀÚÀå °­µµ
  • maximum intensity projection
    ÃÖ´ë°­µµ Åõ»ç
  • maximum safe intensity level
    ÃÖ´ë¾ÈÀü°­µµ.
  • peak intensity
    ÃÖ°í °­µµ (õÌÍÔ Ë­Óø), ÃÖ°í (õÌÍÔ) ¼¼±â
  • peak intensity
    ÃÖ°í °­µµ, ÃÖ°í ¼¼±â
  • radiant intensity
    ¹æ»ç°­µµ(Û¯ÞÒË­öô).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high-energy phosphate donor
    °í(ÍÔ)¿¡³ÊÁö ÀÎ»ê°ø¿©ÀÚ(×òß«Íêæ¨í­)
  • high-level promoter
    °íÀ§(ÍÔêÈ)ÇÁ·Î¸ðÅÍ
  • high-lipid lipoprotein
    °íÁöÁú ÁöÁú´Ü¹éÁú(ÍÔò·òõò¢òõÓ±ÛÜòõ)
  • high-mannose glycoproteins
    ´Ù(Òý)¸¸³ë½º ´ç´Ü¹éÁú(ÓØÓ±ÛÜòõ)
  • high-mannose oligosaccharides
    ´Ù(Òý)¸¸³ë½º °ú´çÁú(ÍûÓØòõ)
  • high-mobility group
    °íÀ̵¿µµ ±º(ÍÔì¹ÔÑÓøÏØ)
  • high-performance liquid chromatography
    °í¼º´É(ÍÔàõÒö) ¾×ü(äûô÷) Å©·Î¸¶Åä±×·¡ÇÇ
  • high-potential iron protein
    °íÀüÀ§(ÍÔï³êÈ) ö´Ü¹éÁú(ôÑÓ±ÛÜòõ)
  • high-pressure liquid chromatography
    °í¾Ð(ÍÔäâ) ¾×ü(äûô÷)Å©·Î¸¶Åä±×·¡ÇÇ
  • high-quality proteins
    °í±Þ ´Ü¹éÁú(ÍÔÐäÓ±ÛÜòõ)
  • high-speed sedimentation equilibrium
    "°í¼Ó ħ°­ÆòÇü(ÍÔáÜöØË½øÁû¬)(¹ý,Ûö)"
  • high-temperature protection regulon
    °í¿Âº¸È£(ÍÔè®ÜÁûÞ) ·¹±Ö·Ð
  • high-temperature-short-time method
    °í¿Â ´Ü½Ã°£¹ý(ÍÔè®Ó­ãÁÊàÛö)
  • high-voltage electrophoresis
    °íÀü¾Ð Àü±â¿µµ¿(ÍÔï³äâï³Ñ¨ç¶ÔÑ)
  • very high-density lipoprotein
    Ãʰí¹Ðµµ(õ±ÍÔÚËÓø) ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high cellular component
    °í¼¼Æ÷±¸¼º¼ººÐ
  • high echo area
    °í¿¡ÄÚ ±¸¿ª
  • high energy
    °í¿¡³ÊÁö
  • high energy radiation
    °íÀü¾ÐÁ¶»ç
  • high field MR scanner
    °íÀÚÀå ÀÚ±â°ø¸í½ºÄ³³Ê
  • high frequency
    °íºóµµ, °íÁÖÆÄ
  • high output heart failure
    °í¹ÚÃ⼺½ÉºÎÀü
  • high power application
    °íÃâ·ÂÀû¿ë
  • high protein diet
    °í´Ü¹é½ÄÀÌ
  • high quality scanning
    °íÁúÀÇ ½ºÄ³´×
  • high resolution
    °íÇØ»ó(µµ)
  • high resolution computed tomography [=HRCT]
    °íÇØ»óÀü»êÈ­´ÜÃþÃÔ¿µ¼ú
  • high risk group
    °íÀ§Çèµµ±º
  • high spatial frequency algorithm
    °í°ø°£Á֯ļö¿¬»ê
  • high speed
    °í¼ÓÀÇ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HPLC high-performance liquid chromatography; high-power liquid chromatography; high-pressure liquid chrom...
HT Hashimoto thyroiditis; hearing test; hearing threshold; heart; heart transplantation, heart transpla...
HIFU High Intensity Focused Ultrasound
GnRH Gonadotropin Releasing Hormone  [HP 1898, 2034]
  = LHRH
  = Go...
DSP decreased sensory perception; delayed sleep phase; desmoplakin; dibasic sodium phosphate; digital si...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DI Dose Intensity
FI Fluorescence intensity
I Intensity
IMRT Intensity Modulated Radiation Therapy
IMRT Intensity Modulated Radiotherapy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • expressive or signal output process
    Ç¥Çö¼º, ȤÀº ½ÅÈ£ÀÇ Ãâ·ÂÈ­ °úÁ¤
  • flow signal
    À¯µ¿ ½ÅÈ£
  • nociceptive signal
    Ä§ÇØ ¼ö¿ë¼º ½ÅÈ£, À¯ÇØ ¼ö¿ë¼º ½ÅÈ£
  • number of signal average
    ½ÅÈ£ Æò±Õ ȸ¼ö
  • quadrature signal detection
    ±¸Àû ½ÅÈ£ ŽÁö
  • signal alteration
    ½ÅÈ£ º¯°æ
  • signal averaging
    ½ÅÈ£ Æò±Õ
  • signal homogeneity
    ½ÅÈ£ ±ÕÀϼº
  • signal loss
    ½ÅÈ£ ¼Ò½Ç
  • signal peptide
    ½ÅÈ£ ÆéƼµå
  • signal symptom
    °æ°í Áõ»ó
  • signal-to-noise ratio
    ½ÅÈ£-ÀâÀ½ºñ, ½ÅÈ£´ë ¼ÒÀ½ ºñÀ²
  • admixed high-copper alloy
    È¥ÇÕÇü °íµ¿ÇÕ±Ý
    °íµ¿ÇÕ±ÝÀÇ °¡Àå ¿À·¡µÈ ÇüÅ·μ­ Àº, ÁÖ¼®, 6% ÀÌÇÏÀÇ ±¸¸®¸¦ ÇÔÀ¯ÇÑ Àç·¡Çü Àúµ¿ÇԱݰú ´ë°Ô ±¸¸®°¡ ¸¹Àº Àº-±¸¸® °øÁ¤ ÇÕ±ÝÀÇ µÎ °¡Áö ºÐ¸»À» È¥ÇÕÇÏ¿© ±¸¸®ÀÇ ÃÑ·®À» Áõ°¡½ÃŲ °ÍÀÌ´Ù. Àúµ¿ Àç·¡Çü ÇÕ±ÝÀº Àý»èÇüÀÌ¸ç °íµ¿ÇÕ±ÝÀº ±¸»óÇüÀ̾ °á°úÀûÀ¸·Î Àý»èÇü°ú ±¸»óÇüÀÌ È¥ÇÕµÈ °ÍÀÌ´Ù.
  • high arched
    ³ôÀº ±¸°³±Ã
  • high cellular component
    °í¼¼Æ÷ ±¸¼º ¼ººÐ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
signal peptides Additional polypeptide sequence of 25 to 30 residues at the amino-terminal or carboxy-terminal end of proteins. The signal sequence signals the cellular fate or destination of a newly synthesised protein directing it to its ultimate destination in the cell. These leaders are recognised by the signal recognition particle and bound by specific receptor sites on the outer surface of the endoplasmic reticulum. They are then transported into the cisterna of the endoplasmic reticulum and from there directed to their ultimate destination in the cell. In prokaryotes, the signal peptides attach to the plasma membrane. These signal sequences are ultimately removed by specific peptidases.
(12 Dec 1998)
signal processing, computer-assisted Computer-assisted processing of electric, ultrasonic, or electronic signals to interpret function and activity.
(12 Dec 1998)
signal recognition particle A complex between a 7S RNA and six proteins. SRP binds to the nascent polypeptide chain of eukaryotic proteins with a signal sequence and halts further translation until the ribosome becomes associated with the rough endoplasmic reticulum. One of the SRP proteins (srp54) binds GTP and in association with 7SRNA and srp19 has GTPase activity.
(18 Nov 1997)
signal recognition particle receptor Receptor for the signal recognition particle (SRP) found in the membrane of the endoplasmic reticulum. Also called docking protein. Heterodimeric, both protomers having GTP binding capacity, though dissimilar binding sites. Not until the complex of SRP, ribosome, message and nascent polypeptide chain binds to the SRP receptor is the block to further chain elongation released and concurrently the SRP is released, leaving the ribosome attached to the endoplasmic reticulum membrane. Cotranslational transport of the polypeptide delivers it into the lumen of the ER.
(18 Nov 1997)
signal response coupling The cascade of processes by which an extracellular signal (typically a hormone or neurotransmitter) interacts with a receptor at the cell surface, causing a change in the level of a second messenger for example calcium or cyclic AMP) and ultimately effects a change in the cells functioning (for example: triggering glucose uptake or initiating cell division). Can also be applied to sensory signal transduction, for example of light at photoreceptors.
(18 Nov 1997)
signal sequence A peptide present on proteins that are destined either to be secreted or to be membrane components. It is usually at the N terminus and normally absent from the mature protein. Normally refers to the sequence (ca 20 amino acids) that interacts with signal recognition particle and directs the ribosome to the endoplasmic reticulum where co translational insertion takes place. Could also refer to sequences that direct post translational uptake by organelles. Signal peptides are highly hydrophobic but with some positively charged residues. The signal sequence is normally removed from the growing peptide chain by signal peptidase, a specific protease located on the cisternal face of the endoplasmic reticulum.
See: signal recognition particle.
(18 Nov 1997)
signal-to-noise ratio <microscopy> Also sometimes used as an abbreviation for serial number, can be somewhat confusing in the case of electronic equipment.
(05 Aug 1998)
signal transduction The cascade of processes by which an extracellular signal (typically a hormone or neurotransmitter) interacts with a receptor at the cell surface, causing a change in the level of a second messenger for example calcium or cyclic AMP) and ultimately effects a change in the cells functioning (for example: triggering glucose uptake or initiating cell division). Can also be applied to sensory signal transduction, for example of light at photoreceptors.
(18 Nov 1997)
signal void In magnetic resonance imaging, a region emitting no radiofrequency signal, either because there are no activated protons in the region (such as flowing blood) or because a different element predominates, particularly calcium.
(05 Mar 2000)
nuclear localization signal Short, predominantly basic amino acid sequences identified as nuclear import signals for some proteins. These sequences are believed to interact with specific receptors at nuclear pores.
(12 Dec 1998)
blood pressure, high High blood pressure (hypertension) is a repeatedly elevated blood pressure exceeding 140 over 90 mmHg. High blood pressure is also called the silent killer. Chronically high blood pressure can cause blood vessel changes in the back of the eye (retina), thickening of the heart muscle, kidney failure, and brain damage. No specific cause for high blood pressure is found in 95% of patients. High blood pressure is treated with salt restriction, regular aerobic exercise, and medications.
(12 Dec 1998)
blood sugar, high Elevated levels of blood glucose (hyperglycaemia) can be found in a number of conditions. The hyperglycaemia leads to spillage of glucose into the urine, hence the term sweet urine. (Diabetes mellitus means sweet urine. )
(12 Dec 1998)
cardiac output, high A state of elevated cardiac output. Conditions that lower peripheral vascular resistance, such as anaemia, arteriovenous fistulas, thyrotoxicosis, and pregnancy, are among the most important factors augmenting the venous return and therefore elevating cardiac output. Increased cardiac output also occurs in muscular exercise, fever, and severe anoxia.
(12 Dec 1998)
radiotherapy, high-energy Radiotherapy using high-energy (megavolt or higher) ionizing radiation. Types of radiation include gamma rays, produced by a radioisotope within a teletherapy unit; X-rays, electrons, protons, alpha particles (helium ions) and heavy charged ions, produced by particle acceleration; and neutrons and pi-mesons (pions), produced as secondary particles following bombardment of a target with a primary particle.
(12 Dec 1998)
mean higher high water <marine biology> The average height of the higher high water over a 19-year period. For shorter periods of observation, corrections are applied to eliminate known variations and reduce the result to the equivalent of a mean 19-year value.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • home signal
    Àå³» ½ÅÈ£±â(¿ª±¸³» ÁøÀÔ ¿©ºÎ¸¦ ¾Ë¸²)
  • interval signal
    (¶óµð¿À ÇÁ·Î»çÀÌÀÇ)¼Û½Å°è¼Ó½ÅÈ£
  • signal
    ½ÅÈ£;±ºÈ£;µµÈ­¼±;¦ÆÐ¿¡°Ô º¸³»´Â ¾ÏÈ£ÀÇ ¼ö;½ÅÈ£(¿ë)ÀÇ;¶Ù¾î³­;ÈǸ¢ÇÑ;½ÅÈ£(±ºÈ£)·Î ¾Ë¸®´Ù;...ÀÇ ÀüÁ¶°¡ µÇ´Ù
  • signal tower
    (öµµÀÇ) ½ÅÈ£¼Ò
  • storm signal
    ÆøÇ³¿ì ½ÅÈ£
  • time signal
    ½Ãº¸
  • breast-high
    °¡½¿±îÁö ³ôÀÌÀÇ
  • high
    ³ôÀº,°í±ÞÀÇ,³ôÀÌ
  • high time
    ²À ¾Ë¸ÂÀº ¶§
  • high-colored
    ¼±¸íÇÑ »öÁ¶ÀÇ
  • high-coloured
    ¼±¸íÇÑ »öÁ¶
  • high-muck-a-muck
    ³ôÀº »ç¶÷
  • high-muckety-muck
    ³ôÀº »ç¶÷
  • high-spirited
    ±â¿îÂù
  • high-tone
    °¡¶ôÀÌ ³ôÀº
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á